Pathological predictors for site of local recurrence after radiotherapy for prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 82, Issue 3, 2012, Pages

  Chopra, Supriya ^a,b   Toi, Ants ^b,c   Taback, Nathan ^d   Evans, Andrew ^b,d   Haider, Masoom A ^b,c,e   Milosevic, Michael ^a,b   Bristow, Robert G ^a,b   Chung, Peter ^a,b   Bayley, Andrew ^a,b   Morton, Gerard ^a,f   Vesprini, Danny ^a,f   Warde, Padraig ^a,b   Catton, Charles ^a,b   Ménard, Cynthia ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^f DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Local recurrence; Predictive factors; Prostate cancer; Radiotherapy

Indexed keywords

BIOPSY; RADIOTHERAPY; SEXTANTS; TUMORS; UROLOGY;

BIOCHEMICAL FAILURE; LOCAL RECURRENCE; METHODS AND MATERIALS; PREDICTIVE FACTORS; PROSTATE CANCERS; SPATIALLY RESOLVED; STATISTICAL SIGNIFICANCE; TARGETED RADIOTHERAPY;

DISEASES;

ADULT; AGED; BIOCHEMISTRY; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LOCAL RECURRENCE; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; REVIEW;

EID: 84856397760     PISSN: 03603016     EISSN: 1879355X     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2011.05.035     Document Type: Article

References (43)

1. J.M. Michalski, K. Bae, and M. Roach Long-term toxicity following 3d conformal radiation therapy for prostate cancer from the RTOG 9406 Phase I/II Dose Escalation Study Int J Radiat Oncol Biol Phys 76 2010 14 22
2. D.A. Kuban, S.L. Tucker, and L. Dong Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer Int J Radiat Oncol Biol Phys 70 2008 67 74
3. D.A. Kuban, L.B. Levy, and M.R. Cheung Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int J Radiat Oncol Biol Phys 79 2011 1310 1317
4. A.L. Zietman, K. Bae, and J.D. Slater Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: Long-term results from Proton Radiation Oncology Group/American College Of Radiology 95-09 J Clin Oncol 28 2006 1106 1111
5. D.P. Dearnaley, M.R. Sydes, and J.D. Graham Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial Lancet Oncol 8 2007 475 487
6. S.T.H. Peeters, W.D. Heemsbergen, and P.C.M. Koper Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch Multicenter Randomized Phase III Trial comparing 68 Gy of radiotherapy with 78 Gy J Clin Oncol 24 2006 1990 1996
7. W.A. Tome, and J.F. Fowler Selective boosting of tumor subvolumes Int J Radiat Oncol Biol Phys 48 2000 593 599
8. A.K. Singh, P. Guion, and N. Sears-Crouse Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: Early results of a Phase I NCI study Radiat Oncol 2 2007 36
9. E.N. van Lin, J.J. Futterer, and S.W. Heijmink IMRT boost dose planning on dominant intraprostatic lesions: Gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI Int J Radiat Oncol Biol Phys 65 2006 291 303
10. V. Fonteyne, G. Villeirs, and B. Speleers Intensity-modulated radiotherapy as primary therapy for prostate cancer: Report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion Int J Radiat Oncol Biol Phys 72 2008 799 807
11. G. De Meerleer, G. Villeirs, and S. Bral The magnetic resonance detected intraprostatic lesion in prostate cancer: Planning and delivery of intensity-modulated radiotherapy Radiother Oncol 75 2005 325 333
12. J. Pouliot, Y. Kim, and E. Lessard Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging Int J Radiat Oncol Biol Phys 59 2004 1196 1207
13. N. Cellini, A.G. Morganti, and G.C. Mattiucci Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: Implications for conformal therapy planning Int J Radiat Oncol Biol Phys 53 2002 595 599
14. D. Pucar, H. Hricak, and A. Shukla-Dave Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: Magnetic resonance imaging and step-section pathology evidence Int J Radiat Oncol Biol Phys 69 2007 62 69
15. E.T. Ruijter, C.A. van de Kaa, and J.A. Schalken Histological grade heterogeneity in multifocal prostate cancer. Biological and clinical implications J Pathol 180 1996 295 299
16. L. Schoenfield, J.S. Jones, and C.D. Zippe The incidence of high-grade prostatic intraepithelial neoplasia and atypical glands suspicious for carcinoma on first-time saturation needle biopsy, and the subsequent risk of cancer BJU Int 99 2007 770 774
17. Consensus statement: Guidelines for PSA following radiation therapy American Society for Therapeutic Radiology and Oncology Consensus Panel Int J Radiat Oncol Biol Phys 37 1997 1035 1041
18. M. Roach 3rd, G. Hanks, and H. Thames Jr. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference Int J Radiat Oncol Biol Phys 65 2006 965 974
19. J. Crook, S. Malone, and G. Perry Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients Int J Radiat Oncol Biol Phys 48 2000 355 367
20. J. Crook, S. Robertson, and G. Collin Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate Int J Radiat Oncol Biol Phys 27 1993 31 37
21. A. Toi, M.G. Neill, and G.A. Lockwood The continuing importance of transrectal ultrasound identification of prostatic lesions J Urol 177 2007 516 520
22. S. Egawa, T.M. Wheeler, and P.T. Scardino The sonographic appearance of irradiated prostate cancer Br J Urol 68 1991 172 177
23. M.A. Haider, P. Chung, and J. Sweet Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy Int J Radiat Oncol Biol Phys 70 2008 425 430
24. Donner A, Klar N. Design and analysis of cluster randomization trials in health research London:Arnold; 2000.
25. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974
26. E. Kuligowska, M.A. Barish, and H.M. Fenlon Predictors of prostate carcinoma: Accuracy of gray-scale and color Doppler US and serum markers Radiology 220 2001 757 764
27. G.P. Kokeny, G.G. Cerri, and L.M. de Oliveira Cerri Correlations among prostatic biopsy results, transrectal ultrasound findings and PSA levels in diagnosing prostate adenocarcinoma Eur J Ultrasound 12 2000 103 113
28. S.W. Melchior, and M.K. Brawer Role of transrectal ultrasound and prostate biopsy J Clin Ultrasound 24 1996 463 471
29. F. Lee, S. Torp-Pedersen, and P.J. Littrup Hypoechoic lesions of the prostate: Clinical relevance of tumor size, digital rectal examination, and prostate-specific antigen Radiology 170 1989 29 32
30. T. Kara, D. Akata, and F. Akyol The value of dynamic contrast-enhanced MRI in the detection of recurrent prostate cancer after external beam radiotherapy: Correlation with transrectal ultrasound and pathological findings Diagn Interv Radiol 17 2011 38 43
31. X. Gao, N. Mohideen, and R.C. Flanigan The extent of biopsy involvement as an independent predictor of extraprostatic extension and surgical margin status in low risk prostate cancer: Implications for treatment selection J Urol 164 2000 1982 1986
32. V. Ravery, C. Chastang, and M. Toublanc Percentage of cancer on biopsy cores accurately predicts extracapsular extension and biochemical relapse after radical prostatectomy for T1-T2 prostate cancer Eur Urol 37 2000 449 455
33. R. Villamon-Fort, J.M. Martinez-Jabaloyas, and P. Soriano-Sarria Percentage of cancer in prostate biopsies as prognostic factor for staging and postoperative biochemical failure after radical prostatectomy Urol Int 78 2007 328 333
34. H.U. Ahmed, C. Moore, and M. Emberton Minimally-invasive technologies in uro-oncology: The role of cryotherapy, HIFU and photodynamic therapy in whole gland and focal therapy of localised prostate cancer Surg Oncol 18 2009 219 232
35. V. Mouraviev, J.M. Mayes, and T.J. Polascik Pathologic basis of focal therapy for early-stage prostate cancer Nat Rev Urol 6 2009 205 215
36. M. Noguchi, T.A. Stamey, and J.E. McNeal Prognostic factors for multifocal prostate cancer in radical prostatectomy specimens: Lack of significance of secondary cancers J Urol 170 2003 459 463
37. A.M. Wise, T.A. Stamey, and J.E. McNeal Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens Urology 60 2002 264 269
38. J.A. Jung, F.V. Coakley, and D.B. Vigneron Prostate depiction at endorectal MR spectroscopic imaging: Investigation of a standardized evaluation system Radiology 233 2004 701 708
39. K. Stamatiou, A. Alevizos, and V. Karanasiou Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer Urol Int 78 2007 313 317
40. D. Pucar, T. Sella, and H. Schoder The role of imaging in the detection of prostate cancer local recurrence after radiation therapy and surgery Curr Opin Urol 18 2008 87 97
41. S. Egawa, T.M. Wheeler, and D.R. Greene Detection of residual prostate cancer after radiotherapy by sonographically guided needle biopsy Urology 39 1992 358 363
42. J.I. Epstein, H. Sanderson, and H.B. Carter Utility of saturation biopsy to predict insignificant cancer at radical prostatectomy Urology 66 2005 356 360
43. A.S. Ishkanian, C.A. Mallof, and J. Ho High-resolution array CGH identifies novel regions of genomic alteration in intermediate-risk prostate cancer Prostate 69 2009 1091 1100